ProCE Banner Activity

Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool

Tool

Get recommendations from 5 experts on individualizing adjuvant therapy for your specific patient with HER2-negative early breast cancer using this Interactive Decision Support Tool.

Released: August 22, 2024

Expiration: August 21, 2025

Share

Faculty

Laura Huppert

Laura Huppert, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Reshma Mahtani

Reshma Mahtani, DO

Chief of Breast Medical Oncology
Miami Cancer Center
Baptist Health South Florida
Miami, Florida

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Tiffany A Traina

Tiffany A Traina, MD, FASCO

Associate Attending, Breast Medicine Service
Vice Chair, Department of Medicine
Section Head, TNBC Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Disclosure

Primary Author

Laura Huppert, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Laura Huppert, MD: consultant/advisor/speaker: AstraZeneca, Pfizer.

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Mersana, Merck, Myovant, Puma Technology, Seattle Genetics, Silicon Biosystems, Takeda.

Reshma Mahtani, DO

Chief of Breast Medical Oncology
Miami Cancer Center
Baptist Health South Florida
Miami, Florida

Reshma Mahtani, DO: consultant/advisor: Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Gilead, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, Seagen, Sermonix, Stemline.

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: Genentech, Gilead, Lilly, Merck.

Tiffany A Traina, MD, FASCO

Associate Attending, Breast Medicine Service
Vice Chair, Department of Medicine
Section Head, TNBC Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, New York

Tiffany A. Traina, MD, FASCO: consultant/advisor: AstraZeneca, BioTheranostics, Daiichi Sankyo, Exact Sciences, G1 Therapeutics, GE Healthcare, Genentech/Roche, Gilead, GlaxoSmithKline, Hengrui, Merck, Novartis, Pfizer, Stemline, TerSera; researcher (paid to institution): Astellas, AstraZeneca, Ayala, Daiichi Sankyo, Genentech/Roche, Pfizer.